Research programme: selective kinase inhibitors - BioMed X/ Merck

Drug Profile

Research programme: selective kinase inhibitors - BioMed X/ Merck

Latest Information Update: 07 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioMed X; Merck & Co; University of Heidelberg
  • Class Small molecules
  • Mechanism of Action DNA repair enzyme modulators; Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Cancer; Inflammation

Most Recent Events

  • 03 Mar 2016 BioMed X and Merck extend agreement to co-develop DNA damage and repair mechanisms therapeutics in Germany for Cancer
  • 13 Jan 2016 Merck acquires all generated research and development results in the field of selective kinase inhibitors from BioMed X
  • 13 Jan 2016 Early research in Cancer in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top